Immunogenetics and the design of Plasmodium falciparum vaccines for use in malaria-endemic populations

Journal of Clinical Investigation

Volumn 110, Issue 3, 2002, Pages 295-301

  Plebanski, Magdalena ^a   Proudfoot, Owen ^a   Pouniotis, Dodie ^a   Coppel, Ross L ^b   Apostolopoulos, Vasso ^a   Flannery, Graham ^c  

^a AUSTIN RESEARCH INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c LA TROBE UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD36 ANTIGEN; DNA; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MALARIA VACCINE; MEMBRANE ANTIGEN; NITRIC OXIDE SYNTHASE; POLYPEPTIDE; PROTOZOAL PROTEIN; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ALLELE; ANTIGEN BINDING; ANTIGEN PRESENTATION; BRAIN MALARIA; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DISEASE SEVERITY; DRUG DESIGN; DRUG EFFICACY; ENDEMIC DISEASE; GENE EXPRESSION; GENE MAPPING; GENETIC CODE; GENETIC POLYMORPHISM; HUMAN; IMMUNE STATUS; IMMUNOREGULATION; MALARIA; MULTIGENE FAMILY; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTECTION; REVIEW;

EID: 0036322371     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI0216163     Document Type: Review

References (67)

1. Estimating mortality, morbidity, and disability due to malaria among Africa's non-pregnant population
2. Genetic susceptibility to malaria getting complex
3. Mannose binding protein deficiency is not associated with malaria, hepatitis B carriage nor tuberculosis in Africans
4. Mannose-binding lectin plasma levels and gene polymorphisms in Plasmodium falciparum malaria
5. Inducible nitric oxide synthase polymorphism and fatal cerebral malaria
6. Nitric oxide synthase 2(Lambarene) (G-954C), increased nitric oxide production, and protection against malaria
7. CR1 density polymorphism on erythrocytes of falciparum malaria patients in Thailand
8. +) continuously migrate through lymphoid organs: Within the tissue they alter surface molecule expression
9. A high frequency African coding polymorphism in the N-terminal domain of ICAM-1 predisposing to cerebral malaria in Kenya
10. Malaria susceptibility and CD36 mutation
11. A non-sense mutation in Cd36 gene is associated with protection from severe malaria
12. Plasmodium falciparum-infected erythrocytes modulate the maturation of dendritic cells
13. Absence of an association between intercellular adhesion molecule 1, complement receptor 1 and interleukin 1 receptor antagonist gene polymorphisms and severe malaria in a West African population
14. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria
15. Genetic susceptibility to malaria and other infectious diseases: From the MHC to the whole genome
16. Severe malarial anemia and cerebral malaria are associated with different tumor necrosis factor promoter alleles
17. TNFalpha*2 marks high risk of severe disease during Plasmodium falciparum malaria and other infections in Sri Lankans
18. Alleles and haplotypes of tumor necrosis factor (TNF) alpha and beta genes in three ethnic populations of Sulawesi, Indonesia
19. The immunology of malaria infection
20. Th1/Th2 effector choice in parasitic infection: Decision making by committee
21. Precursor frequency analysis of cytotoxic T lymphocytes to pre-erythrocytic antigens of Plasmodium falciparum in West Africa
22. Common west African HLA antigens are associated with protection from severe malaria
23. Identification of conserved antigenic components for a cytotoxic T lymphocyte-inducing vaccine against malaria
24. Molecular analysis of the association of HLA-B53 and resistance to severe malaria
25. HLA-DQB1*0501-restricted Th1 type immune responses to Plasmodium falciparum liver stage antigen 1 protect against malaria anemia and reinfections
26. The presence of the HLA class II allele DPB1*0501 in ethnic Thais correlates with an enhanced vaccine-induced antibody response to a malaria sporozoite antigen
27. Interaction of HLA and age on levels of antibody to Plasmodium falciparum rhoptry-associated proteins 1 and 2
28. HLA alleles in relation to specific immunity to liver stage antigen-1 from Plasmodium falciparum in Gabon
29. Chromosomal mapping of the host resistance locus to rodent malaria (Plasmodium yoelii) infection in mice
30. Identification of a new malaria susceptibility locus (Char4) in recombinant congenic strains of mice
31. Mouse loci for malaria-induced mortality and the control of parasitaemia
32. PfEMP1, polymorphism and pathogenesis
33. Fcgamma receptor IIa (CD32) polymorphism is associated with protection of infants against high-density Plasmodium falciparum infection. VII. Asembo Bay Cohort Project
34. Naturally acquired antibody responses to Plasmodium falciparum merozoite surface protein 4 in a population living in an area of endemicity in Vietnam
35. Contrasting functions of IgG and IgE antimalarial antibodies in uncomplicated and severe Plasmodium falciparum malaria
36. IgE deposition in brain microvessels and on parasitized erythrocytes from cerebral malaria patients
37. Genetic variation and the recent worldwide expansion of Plasmodium falciparum
38. Recent origin of Plasmodium falciparum from a single progenitor
39. Origin of Plasmodium falciparum malaria is traced by mitochondrial DNA
40. The ecology of genetically diverse infections
41. Imperfect vaccines and the evolution of pathogen virulence
42. Association of malaria parasite population structure, HLA, and immunological antagonism
43. Immune evasion in malaria: Altered peptide ligands of the circumsporozoite protein
44. Altered peptide ligands narrow the repertoire of cellular immune responses by interfering with T-cell priming
45. Interleukin 10-mediated immunosuppression by a variant CD4 T cell epitope of Plasmodium falciparum
46. IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: Two key steps in specific immunotherapy
47. Identification of frequently recognized dimorphic T-cell epitopes in Plasmodium falciparum merozoite surface protein-1 in West and East Africans: Lack of correlation of immune recognition and allelic prevalence
48. Escape of human immunodeficiency virus from immune control
49. Hepatitis B virus immunopathogenesis
50. Efficacy of recombinant circumsporozoite prorein vaccine regimens against experimental Plasmodium falciparum malaria
51. A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia
52. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: A randomised trial
53. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea
54. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara
55. Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use
56. Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid
57. Induction of T helper type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria
58. Immunization with recombinant Plasmodium yoelii merozoite surface protein 4/5 protects mice against lethal challenge
59. Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3
60. Drug treatment of tropical parasitic infections: Recent achievements and developments
61. A polymorphism that affects OCT-1 binding to the TNF promoter region is associated with severe malaria
62. Immune effector mechanisms in malaria
63. Vaccines for preventing malaria
64. Phase I/Ila safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria
65. + type 1 responses in humans by a malaria DNA vaccine
66. Phase I trial of two recombinant vaccines conraining the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid
67. Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers